Explore more publications!

New research rules out autism risk from paracetamol in pregnancy

(MENAFN) A recent study published on Friday has found no connection between the use of paracetamol, commonly associated with the Tylenol brand in the United States, during pregnancy and the development of autism, contradicting earlier claims made by US President Donald Trump.

"Current evidence does not indicate a clinically important increase in the likelihood of autism spectrum disorder, ADHD, or intellectual disability in children of pregnant individuals who use paracetamol as directed, supporting existing recommendations on its safety," the study stated, according to reports.

The research team conducted a systematic review of existing studies, searching major medical databases for evidence on whether paracetamol exposure during pregnancy is associated with autism, attention deficit hyperactivity disorder (ADHD), or intellectual disability. They focused on studies that compared pregnancies with and without paracetamol use, utilizing medical records and validated questionnaires to assess child development outcomes.

In total, 43 studies were included in the systematic review, and 17 studies were analyzed in the meta-analysis.

"When we did this analysis, we found no links, there was no association, there's no evidence that paracetamol increases the risk of autism," lead author Asma Khalil told reports. She added: "The message is clear – paracetamol remains a safe option during pregnancy when taken as guided."

The findings counter claims made in September by US President Trump, who suggested that using Tylenol during pregnancy could be linked to a “significantly increased risk of autism.”

Public health authorities widely rejected these assertions, which are consistent with Trump’s previous tendency to promote unverified health claims during his presidency, including throughout the COVID-19 pandemic.

MENAFN18012026000045017640ID1110612565


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions